B
aseline predictors of sustained virologic response (SVR) to interferon-based therapies include interleukin (IL)-28B polymorphism, viral load, genotype, age, ethnicity, body weight, insulin resistance, steatosis, and fibrosis stage. [1] [2] [3] On-treatment viral kinetics have been more predictive of SVR, particularly the degree of virologic decline at weeks 4 and 12. 4, 5 In a large prospective study of HCV genotype 1 patients treated with peginterferon-ribavirin, 5 genomewide association analysis revealed several host single nucleotide polymorphisms (SNPs) on chromosome 19, near the IL-28B gene, that were associated strongly with SVR. 3, 6 Patients homozygous for the CC allele of the SNP rs12979860 had higher SVR rates compared with those with the CT or TT alleles. Differences in genotype prevalence partially explained the lower SVR rates among black patients. Several other reports have corroborated these findings. 7, 8 Another SNP, rs8099917, also has been reported to show predictive utility for SVR. 9 The favorable homozygous TT variant was associated with higher SVR rates compared with the GT or GG variants. This assay has now become commercially available along with the rs12979860. A recent cross-analysis of these 2 published SNPs found for those with the rs12979860 CC variant, additional genotyping of the rs8099917 SNP had no impact on response prediction, whereas those with the rs12979860 TT variant benefited with respect to SVR prediction by additional genotyping of the rs8099917 SNPs. 9 Data from 2 large phase 3 trials that assessed the NS3/4A protease inhibitor, boceprevir, recently were published. 10, 11 SVR rates with boceprevir plus peginterferonribavirin significantly improved SVR compared with peginterferon-ribavirin control. The boceprevir regimens used a 4-week lead-in period with peginterferon-ribavirin before adding boceprevir. In multivariate regression analyses, baseline predictors of SVR in previously treated patients included assignment to a boceprevir group rather than the control group, previous relapse vs previous nonresponse, low viral load at baseline, and absence of cirrhosis. In previously untreated patients, baseline predictors of SVR included assignment to a boceprevir group rather than the control group, race, low viral load at baseline, age, statin use, and absence of cirrhosis. In both studies, good response to interferon, defined as a Ն1 log 10 IU/mL decline in HCV-RNA level after the 4-week lead-in, was the strongest predictor of SVR.
The role of IL-28B in combination with other baseline factors in predicting interferon response, as defined by the 4-week peginterferon-ribavirin lead in, and, ultimately, SVR in HCV protease inhibitor-containing regimens, remains undefined. 12 We assessed the relationship and utility of baseline factors and their association with SVR and early viral kinetics in boceprevir-based regimens in previously untreated and previous treatment-failure genotype 1 hepatitis C patients.
Materials and Methods

Study Design and Objectives
Two phase 3 boceprevir (Victrelis; Merck Sharp & Dohme, Corp, Whitehouse Station, NJ) trials in previously untreated (SPRINT-2, n ϭ 1097) and previous treatment-failure patients (RESPOND-2, n ϭ 403; included relapsers and partial responders to peginterferon and ribavirin) have been reported (Supplementary Figure 1) . 10, 11 Previous treatment-failure patients are patients who previously had a partial response (Ն2 log 10 decline in HCV RNA at week 12) to peginterferon-ribavirin or who relapsed after peginterferon-ribavirin therapy. All patients received a 4-week lead-in with peginterferon alfa-2b-ribavirin. Subsequently, the control group received peginterferon alfa-2b-ribavirin plus boceprevir placebo for 44 weeks (PR48); the second group received peginterferon alfa-2b-ribavirin plus boceprevir (24 weeks SPRINT-2; 32 weeks RESPOND-2) using response-guided therapy, whereby patients with undetectable HCV-RNA levels at week 8 were eligible for a shorter (28 weeks SPRINT-2; 36 weeks RESPOND-2) duration of total therapy for rapid responders but continuation of peginterferon-ribavirin therapy to week 48 for slow responders (BOC RGT); and the third group received peginterferon alfa-2b-ribavirin plus boceprevir for 44 weeks (BOC/PR48).
Both studies prospectively consented patients for pharmacogenomic testing and collected samples for biomarker identification. Two optional consents/sample collections occurred. The first one occurred at the onset of the study and consented/ collected future-use samples in which no specific assay or test was mentioned in the consent. For patients who did not consent to pharmacogenomic testing at the onset of the study, an additional consent/sample collection was initiated specifically for IL-28B/ITPA testing following published data. 3 As stated in the original protocols and data analysis plans (available at http:// www.nejm.org), IL-28B genetic classification of patients would be evaluated as a predictor of SVR by frequency tables and logistic regression models. Here, we describe the IL-28B rs12979860 and rs8099917 genotype distribution in the subpopulation of patients with pharmacogenomic samples, evaluate IL-28B rs12979860 genotype as a pretreatment predictor of SVR and early viral kinetics (ie, week 4 and week 8 response), and assess if IL-28B rs12979860 predicts SVR after adjusting for on-treatment interferon response (Ն1 vs Ͻ1-log 10 decline in HCV-RNA level after the 4-week lead-in). In addition, we assessed the concordance between rs12979860 and rs8099917 with respect to SVR.
Other previously well-established predictors of response with pegylated interferon and ribavirin regimens including host and viral demographics were assessed and included in regression analysis models to determine how to predict SVR accurately with boceprevir-based regimens.
Genotyping
IL-28B genotyping for markers rs12979860, rs12980275, and rs8103142 was performed by Gentris Clinical Genetics, Inc (Morrisville, NC), using DNA Sanger Sequencing Technology. Several SNPs in linkage disequilibrium are in this region, and the principal one evaluated has been the rs12979860 locus. Genotype data for rs8099917 were generated using the Illumina 1M Duo chip at the Covance Genomic Laboratory (Seattle, WA).
Statistical Analysis
Analyses were performed on all patients who consented to pharmacogenomic sampling, had sampling data, and received at least one dose of placebo or boceprevir. The proportion of patients achieving SVR and 95% confidence intervals (CI) were summarized by IL-28B rs12979860 genotype (CC, CT, TT) for each treatment group, for both studies. SVR rates and 95% CIs also are displayed by treatment week 4 response (Ͻ1 log 10 decline vs Ն1 log 10 decline), as well as treatment week 8 response (undetectable vs detectable).
Three separate multivariate logistic regression analyses were conducted to evaluate baseline factors, including IL-28B rs12979860 genotype, as predictors of response in patients assigned to receive triple therapy: (1) SVR as the outcome variable; (2) early on-treatment response as the outcome variable, defined as Ͻ1 log 10 decline vs Ն1 log 10 decline in HCV-RNA level at week 4; and (3) SVR as the outcome variable with early on-treatment response modeled as a baseline factor (because week 4 was before the addition of boceprevir). Odds ratio (OR), 95% CI of the ORs, and chi-square P values from the logistic models are presented. These models are considered exploratory and are unadjusted for multiple comparisons.
The proportion of patients achieving SVR and 95% CIs also were summarized by IL-28B rs8099917 genotype (TT, GT, GG) for each treatment group, for both studies. In addition, we performed a post hoc analysis for all patients with poor response to interferon (Ͻ1 log 10 decline at week 4), including those who did not consent to genomic testing, to determine if there are baseline characteristics that are predictive of SVR for patients with poor response to interferon.
Results
Baseline and On-Treatment Predictors of SVR
A total of 1048 (previously untreated, SPRINT-2) and 393 (previous treatment-failure, RESPOND-2) patients completed the peginterferon-ribavirin lead-in phase and received at least one dose of boceprevir or placebo. Logistic regression analysis to assess predictors of SVR was performed in patients who consented to genomic testing (Table 1) . IL-28B genotype data at the rs12979860 locus were available for 653 (62%) and 259 (66%) of SPRINT-2 and RESPOND-2 patients, respectively (Supplementary Figure 2) . The CC genotype was found in 28% (259 of 912), the CT genotype in 54% (491 of 912), and the TT genotype in 18% (162 of 912) ( Table 1 ). The baseline demographic characteristics for patients with rs12979860 data were balanced among the 3 treatment groups. Baseline characteristics of patients with genomic testing as well as SVR rates for those who did and did not consent to genomic testing are shown in Supplementary  Tables 1 and 2 . Overall, in both studies, patients who consented to genomic testing had numerically higher SVR rates than those who did not consent.
SVR rates by IL-28B rs12979860 genotype for previously untreated patients and previous treatment-failure patients are shown in Figure 1 . In previously untreated patients, low baseline viral load (OR, 11.6) was predictive of response, as was favorable IL-28B genotype (rs 12979860 CC vs TT or CT [OR, 2.6, 2.1]), absence of 138 (64) 165 (74) 142 (66) 44 (85) 78 (77) 77 (73) HCV-RNA level, n (%) Յ400,000 IU/mL 20 (9) 19 (9) 11 (5) 4 (8) 6 (6) 15 (7) 19 (9) 20 (9) 11 (21) 22 (22) 20 (19) Missing 8 (4) 11 (5) 3 (1) 2 (4) 8 (8) (65) 68 (64) BOC, boceprevir. a The HCV subtype was ascertained by sequencing of the nonstructural 5B region. b Possible METAVIR fibrosis scores are as follows: a score of 0 indicates no fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal fibrosis with few septa, 3 indicates numerous septa without cirrhosis, and 4 indicates cirrhosis. c Prior nonresponse was defined as a decrease in the HCV-RNA level of at least 2 log 10 IU/mL by week 12 of prior therapy, but a detectable HCV-RNA level throughout the course of prior therapy, without subsequent attainment of a sustained virologic response. Prior relapse was defined as an undetectable HCV-RNA level at the end of prior therapy, without subsequent attainment of a sustained virologic response.
cirrhosis (OR, 4.3), HCV 1b subtype (OR, 2.0), and non-black race (OR, 2.0) ( Table 2 ). In previous treatment-failure patients, the only significant predictor of SVR was previous relapse vs previous nonresponse (OR, 2.6). Although in both studies a low baseline viral load had the largest relative OR, it should be noted that a small proportion of patients in each study had a viral load Յ400,000 (8% [50 of 653] in SPRINT-2 and 5% [13 of 259] in RESPOND-2). As previously reported for both studies, patients with poor response to interferon (Ͻ1 log 10 IU/mL decline at treatment week 4) had substantially lower SVR rates than those with a good response to interferon (Ն1 log 10 IU/mL decline at treatment week 4), as well as higher rates of boceprevir-resistance-associated variants. 10, 11 We therefore performed multivariate analysis to assess baseline factors that predict interferon response. In previously untreated patients, baseline predictors of good response to interferon included IL-28B genotype, low baseline viral load, absence of cirrhosis, and lower body mass index (BMI) ( Table 2 ). In previous treatment-failure patients, baseline predictors of good response to interferon included IL-28B genotype and previous relapse vs previous nonresponse.
Given that in both previously untreated and previous treatment-failure patients, 28%-38% of patients with poor response to interferon who received boceprevir achieved SVR, compared with only 0%-4% in the peginterferonribavirin control arm, we also compared SVR rates by baseline characteristics in these poor interferon responders. Significant differences in SVR rates (Pearson chisquare test) for patients with poor response to interferon who received boceprevir (combined studies) were observed for patients with genotype 1b vs 1a (47% ; P ϭ .002). Nonsignificant differences in SVR were observed for the other baseline factors considered, including sex, race (black vs nonblack), age (Ͻ40 vs Ն40 y), BMI (Յ25, Ͼ25 to 30, Ͼ30), and steatosis score (0 vs Ͼ0).
When the log 10 HCV-RNA decline at week 4 was added to the logistic regression analysis, it was a significant predictor of SVR in previously untreated patients (OR, 8.2) as was low baseline viral load (OR, 8.4), absence of cirrhosis (OR, 3.5), lower BMI (OR, 2.5), and HCV 1b subtype (OR, 2.1) ( Table 2) . IL-28B and race were no longer significant predictors of SVR. In previous treatment-failure patients, the log 10 HCV-RNA decline at week 4 was a significant predictor of SVR (OR, 2.7) as was previous relapse vs previous nonresponse (OR, 2.2). None of the other baseline factors were significant predictors of SVR in the presence of the 4-week peginterferon-ribavirin lead-in.
rs12979860 and rs8099917 IL-28B Concordance
Analyses of SVR based on 2 SNPs were performed, rs12979860 and rs8099917 (Supplementary Table 3 ). Fewer samples were available and genotyped successfully at rs8099917, representing 524 (50%) and 229 (58%) of SPRINT-2 and RESPOND-2 patients, respectively. As with the rs12979860 SNP, the baseline demographic characteristics for patients with rs8099917 data were balanced among the 3 treatment groups. The breakdown of patients at the rs8099917 locus revealed 57% (426 of 753) had the favorable TT genotype, with 39% (293 of 753) having the GT and 5% (34 of 753) having the GG genotypes. A cross-analysis of rs12979860 and rs8099917 SNPs revealed that most CC patients at the rs12979860 locus had the corresponding favorable TT at the rs8099917 locus. However, the converse was not true because TT patients at rs8099917 were as likely to be CC vs non-CC. Patients with the CT genotype at rs12979860 had TT or GT variants at rs8099917 but were not found to have the GG variant, whereas those with the unfavorable TT variant at rs12979860 SNP were more or less evenly distributed across the TT, GT, and GG variants at the rs8099917 SNP. Combining the 2 SNP genotypes did not offer enhanced predictability of SVR (Supplementary Table 3) , and although both rs12979860 and rs8099917 have utility in predicting SVR, it appears the rs12979860 locus is more predictive when considering all treatment groups, including the control groups.
Response Based on rs12979860 IL-28B Status and Selected Baseline Characteristics
SVR rates based on prior response to therapy (nonresponse and relapse), ethnicity, and fibrosis scores for IL-28B rs12979860 genotypes are shown in Table 3 . SVR rates were highest for prior relapsers in each of the treatment groups for each of the IL-28B genotypes. The SPRINT-2 trial enrolled black and non-black patients separately to better assess differences in treatment efficacy. Consistent with the results for Caucasians, black patients with the CC genotype had higher SVR rates than non-CC, regardless of the treatment regimen. Fibrosis stage did not appear to influence results, although there were a limited number of patients with advanced fibrosis.
Response Based on rs12979860 IL-28B Status and Early Viral Kinetics
On-treatment differences in viral load reduction between genotypes were noted immediately after the addition of boceprevir to peginterferon-ribavirin (Figure 2) . In the multivariate analyses, IL-28B CC was the BOC, boceprevir; n, number of patients who achieved SVR; m, number of patients with indicated IL-28B genotype in the respective subgroup. a Possible METAVIR fibrosis scores are as follows: a score of 0 indicates no fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal fibrosis with few septa, 3 indicates numerous septa without cirrhosis, and 4 indicates cirrhosis. b Prior nonresponse was defined as a decrease in the HCV-RNA level of at least 2 log 10 IU/mL by week 12 of prior therapy but a detectable HCV-RNA level throughout the course of prior therapy, without subsequent attainment of a sustained virologic response. Prior relapse was defined as an undetectable HCV-RNA level at the end of prior therapy, without subsequent attainment of a sustained virologic response.
strongest predictor of interferon response, and interferon response ultimately was the strongest predictor of SVR. As shown in Figure 3 , almost all of the patients with the IL-28B CC genotype had good response to interferon (97% [190 of 195] previously untreated; 94% [59 of 63] previous treatment failures). Patients with the rs12979860 CT or TT genotypes who received boceprevir-containing regimens and showed good response to interferon had SVR rates of 67%-85% vs 18%-62% for those with the CT or TT genotypes who received control ( Figure 3A and C) .
In the response-guided therapy groups of both studies (BOC RGT), the duration of therapy was based on a prespecified decision point whereby those with undetectable HCV-RNA levels at week 8 were eligible for shorter therapy. The majority of CC patients treated with boceprevir-containing regimens had undetectable HCV-RNA levels by week 8 (89% [117 of 132] in SPRINT-2; 76% [38 of 50] in RESPOND-2), and hence were eligible for shortened duration of therapy (Supplementary Table 4 128] in RESPOND-2) and TT (42% [36 of 86] in SPRINT-2; 63% [12 of 19] in RESPOND-2) genotypes became undetectable by week 8; however, SVR rates for patients in the boceprevir groups who become undetectable by week 8 were 81%-100%, regardless of IL-28B genotype ( Figure 3B and D) . For the patients with poor response to interferon who received boceprevir, none with a Ͻ3 log 10 decline in HCV RNA at week 8 (0 of 44 patients) achieved SVR (Figure 4 ). Despite having a Ͻ1 log 10 decline at week 4, 40 of 264 patients had undetectable HCV RNA at week 8 and 83% (33 of 40 patients) achieved SVR.
Discussion
These predefined analyses assessed baseline predictors of SVR, including both IL-28B rs12979860 and rs8099917 SNPs, with direct-acting antiviral therapy. These data suggest that pretreatment knowledge of IL-28B can be used to predict which patients will be interferon responsive, and which patients may qualify for a shorter duration of treatment. However, a Ն1-log 10 HCV RNA decline at week 4 was shown to be the strongest overall predictor of SVR.
In previously untreated patients (SPRINT-2), those with the favorable rs12979860 CC genotype had similar SVR rates across the 3 treatment arms. Despite a similar SVR in all groups with the favorable CC genotype, the addition of boceprevir allowed shortening of the total treatment duration from 48 to 28 weeks in nearly 90% of patients. The largest relative gain in efficacy for boceprevir-treated patients (BOC RGT or BOC/PR48 groups) over control (PR48) occurred in patients with the less favorable rs12979860 CT and TT genotypes. Because 83% (78 of 94) of the black and 68% (379 of 559) of the non-black patients in SPRINT-2 had the CT or TT genotype, the majority of patients would benefit from boceprevir-based therapy in terms of increased SVR (59% to 71%) compared with peginterferon-ribavirin alone (27% to 28%), and an added benefit of shortened treatment duration in some.
The current findings show that boceprevir confers a substantial increase in SVR vs peginterferon-ribavirin alone in prior relapsers and nonresponders to peginterferon-ribavirin therapy. Among patients with IL-28B data, prior relapsers had SVR rates of 74%-86% with boceprevir containing regimens compared with 45%-60% for prior nonresponders. For prior nonresponders and relapsers with the CC genotype, the addition of boceprevir resulted in SVR rates of 77%-79% vs 46% for peginterferon-ribavirin alone, and allowed a shortened total duration of therapy to 36 weeks in 76%. Robust comparisons based on race, fibrosis stage, and prior response to therapy were not possible owing to a limited number of patients within some subsets. Despite this limitation, overall data suggest patients with advanced fibrosis will have a higher likelihood of achieving SVR if boceprevir is added to peginterferon-ribavirin, regardless of IL-28B genotype.
The addition of boceprevir to poor interferon responders led to significantly improved SVR rates (28% to 38%) compared with only 0%-4% for those treated with peginterferon-ribavirin alone. However, host and viral baseline predictors further delineate this group of poor responders. Patients with poor response to interferon were almost twice as likely to achieve SVR if they were genotype 1b vs 1a, had a METAVIR score F0/1/2 vs F3/4, or baseline viral load Յ2 M IU/mL vs Ͼ2 M IU/mL. Indeed, these genotype 1b patients had SVR rates of close to 50%. For this population of poorly interferon-responsive patients, a Ͻ3 log 10 decline by week 8 (corresponding to 4 weeks of triple therapy) had a negative predictive value of 100% for achieving SVR. Hence, triple therapy for those with poor interferon response can be as short as 8 weeks, an important early futility time point.
This study had limitations. Approximately one third of patients in these 2 large trials did not consent to genomic testing and the studies were neither designed nor powered to assess the impact of IL-28B genotype on SVR. The subpopulation with IL-28B data was not a random sampling and there were some small differences between the group that consented to pharmacogenomic testing and the overall study population. In addition, the SVR rate in the CC control patients of SPRINT-2 (78%) was higher than some previous reports of 69% (Caucasians), 48% (African Americans), 56% (Hispanics), and 66% (all races combined), 6 and SVR rates for patients in the control and boceprevir arms of both studies who consented to genomic testing were higher than those who did not consent. Therefore, there may have been consent bias because some patients consented to testing after beginning treatment and the study may have underestimated an incremental impact of boceprevir on SVR in patients with the IL-28B rs1299860 CC genotype. It should be noted that the proportion of patients who consented prospectively for pharmacogenomic testing was similar to the large, US phase 3b Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy (IDEAL) study of peginterferon-ribavirin therapy (57%), and in the IDEAL study the decision to consent for pharmacogenomic testing did not introduce selection bias. 6, 13 The current analyses also did not consider adherence to treatment regimen. However, a prior study showed that 57% and 61% of patients in SPRINT-2 and RE-SPOND-2 were compliant with boceprevir dosing (Ͼ80%) and dosing duration (Ͼ80%). 14 The study showed that treatment duration was an important factor associated with SVR, and the recommended 7-to 9-hour boceprevir dosing interval had minimal impact on SVR in patients with more than 80% adherence to dosing.
These data suggest that knowledge of IL-28B genotype pretreatment may be used to predict which patients will have the highest likelihood of receiving a shorter duration of triple therapy, and of SVR itself. These data also suggest that IL-28B at the rs12979860 locus is the strongest pretreatment predictor of interferon responsiveness, whereas the decline in HCV-RNA level at week 4 compared with baseline is an on-treatment measurement of interferon responsiveness, and is ultimately the best overall predictor of SVR. The IL-28B rs8099917 locus appears to have less overall utility as a single marker, or in com- bination with rs12979860, in the patient population studied. The use of IL-28B testing is common now in clinical trials, but its role in practice still is evolving. More potent regimens or an interferon-free regimen may further attenuate or even obviate the need for baseline predictors of response, including IL-28B testing.
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